Iresha Hanchapola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iresha Hanchapola has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Clayton
Department of Biochemistry and Molecular Biology, Monash University Clayton, VIC, Australia
2 shared publications - Patrick Perlmutter
School of Chemistry, Monash University, Wellington Road, Clayton Vic. 3800 (Australia)
2 shared publications A. Ian Smith
Monash University
1 shared publication- Alexander Ian Smith
Department of Biochemistry, Monash University, Melbourne, Australia
1 shared publication - Anthony Wayne Purcell
Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia
1 shared publication - Frederike Schmitz
Dutch Research Council (NWO)
1 shared publication
Latest Publications
- Open Access
- 30 January 2015
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 6, 5
Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2
Angiotensin converting enzyme 2 (ACE2) is a zinc carboxypeptidase involved in the renin angiotensin system (RAS) and inactivates the potent vasopressive peptide angiotensin II (Ang II) by removing the C-terminal phenylalanine residue to yield Ang1-7. This conversion inactivates the vasoconstrictive action of Ang II and yields a peptide that acts as a vasodilatory molecule at the Mas receptor and potentially other receptors. Given the growing complexity of RAS and level of cross-talk between ligands and their corresponding enzymes and receptors, the design of molecules with selectivity for the major RAS binding partners to control cardiovascular tone is an on-going challenge. In previous studies we used single β-amino acid substitutions to modulate the structure of Ang II and its selectivity for ACE2, AT1R and angiotensin type 2 (AT2R) receptor. We showed that modification at the C-terminus of Ang II generally resulted in more pronounced changes to secondary structure and ligand binding, and here we further explore this region for the potential to modulate ligand specificity. In this study, 1) a library of forty-seven peptides derived from the C-terminal tetra-peptide sequence (-IHPF) of Ang II was synthesised and assessed for ACE2 binding, 2) the terminal group requirements for high affinity ACE2 binding were explored by and N- and C-terminal modification, 3) high affinity ACE2 binding chimeric AngII analogues were then synthesized and assessed, 4) the structure of the full-length Ang II analogues were assessed by circular dichroism, and 5) the Ang II analogues were assessed for AT1R/AT2R selectivity by cell-based assays. Studies on the C-terminus of Ang II demonstrated varied specificity at different residue positions for ACE2 binding and four Ang II chimeric peptides were identified as selective ligands for the AT2 receptor. Overall, these results provide insight into the residue and structural requirements for ACE2 binding and angiotensin receptor selectivity.
- 30 January 2015
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 6, 5
Open AccessStructural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2
Angiotensin converting enzyme 2 (ACE2) is a zinc carboxypeptidase involved in the renin angiotensin system (RAS) and inactivates the potent vasopressive peptide angiotensin II (Ang II) by removing the C-terminal phenylalanine residue to yield Ang1-7. This conversion inactivates the vasoconstrictive action of Ang II and yields a peptide that acts as a vasodilatory molecule at the Mas receptor and potentially other receptors. Given the growing complexity of RAS and level of cross-talk between ligands and their corresponding enzymes and receptors, the design of molecules with selectivity for the major RAS binding partners to control cardiovascular tone is an on-going challenge. In previous studies we used single β-amino acid substitutions to modulate the structure of Ang II and its selectivity for ACE2, AT1R and angiotensin type 2 (AT2R) receptor. We showed that modification at the C-terminus of Ang II generally resulted in more pronounced changes to secondary structure and ligand binding, and here we further explore this region for the potential to modulate ligand specificity. In this study, 1) a library of forty-seven peptides derived from the C-terminal tetra-peptide sequence (-IHPF) of Ang II was synthesised and assessed for ACE2 binding, 2) the terminal group requirements for high affinity ACE2 binding were explored by and N- and C-terminal modification, 3) high affinity ACE2 binding chimeric AngII analogues were then synthesized and assessed, 4) the structure of the full-length Ang II analogues were assessed by circular dichroism, and 5) the Ang II analogues were assessed for AT1R/AT2R selectivity by cell-based assays. Studies on the C-terminus of Ang II demonstrated varied specificity at different residue positions for ACE2 binding and four Ang II chimeric peptides were identified as selective ligands for the AT2 receptor. Overall, these results provide insight into the residue and structural requirements for ACE2 binding and angiotensin receptor selectivity.
- 1 January 2009
- Published by Springer Nature
- Vol. 611, 559-560
The active site specificity of angiotensin II converting enzyme 2 investigated through single and multiple residue changes and β-amino acid substrate analogs.
- 1 January 2009
- Published by Springer Nature
- Vol. 611, 559-560
The active site specificity of angiotensin II converting enzyme 2 investigated through single and multiple residue changes and β-amino acid substrate analogs.